JP2002541859A - 化合物スクリーニング方法 - Google Patents
化合物スクリーニング方法Info
- Publication number
- JP2002541859A JP2002541859A JP2000612503A JP2000612503A JP2002541859A JP 2002541859 A JP2002541859 A JP 2002541859A JP 2000612503 A JP2000612503 A JP 2000612503A JP 2000612503 A JP2000612503 A JP 2000612503A JP 2002541859 A JP2002541859 A JP 2002541859A
- Authority
- JP
- Japan
- Prior art keywords
- elegans
- serca
- activity
- protein
- change
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 176
- 150000001875 compounds Chemical class 0.000 title claims abstract description 101
- 238000012216 screening Methods 0.000 title abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 203
- 239000011575 calcium Substances 0.000 claims abstract description 63
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims abstract description 33
- 108091006112 ATPases Proteins 0.000 claims abstract description 28
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims abstract description 28
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 116
- 230000014509 gene expression Effects 0.000 claims description 109
- 210000004027 cell Anatomy 0.000 claims description 82
- 241000244206 Nematoda Species 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 78
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 71
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical group CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims description 71
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims description 70
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 70
- 210000001519 tissue Anatomy 0.000 claims description 68
- 230000002829 reductive effect Effects 0.000 claims description 64
- 230000035772 mutation Effects 0.000 claims description 54
- 230000008859 change Effects 0.000 claims description 50
- 108700019146 Transgenes Proteins 0.000 claims description 49
- 210000003205 muscle Anatomy 0.000 claims description 46
- 230000034958 pharyngeal pumping Effects 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 43
- 230000006399 behavior Effects 0.000 claims description 42
- 230000005764 inhibitory process Effects 0.000 claims description 41
- 108010059929 phospholamban Proteins 0.000 claims description 41
- 102000005681 phospholamban Human genes 0.000 claims description 41
- 239000005090 green fluorescent protein Substances 0.000 claims description 40
- 230000012010 growth Effects 0.000 claims description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 36
- 230000003993 interaction Effects 0.000 claims description 36
- 230000009261 transgenic effect Effects 0.000 claims description 32
- 101100459320 Caenorhabditis elegans myo-2 gene Proteins 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 29
- 101150035353 SERCA gene Proteins 0.000 claims description 29
- 108010041089 apoaequorin Proteins 0.000 claims description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 21
- 229910052791 calcium Inorganic materials 0.000 claims description 21
- 230000003542 behavioural effect Effects 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 230000000692 anti-sense effect Effects 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 15
- 230000001747 exhibiting effect Effects 0.000 claims description 15
- 108020005544 Antisense RNA Proteins 0.000 claims description 13
- 101100149312 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SER1 gene Proteins 0.000 claims description 13
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 101710109118 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 Proteins 0.000 claims description 11
- 102100027733 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 Human genes 0.000 claims description 11
- 210000003905 vulva Anatomy 0.000 claims description 11
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 claims description 10
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 claims description 10
- 210000001184 pharyngeal muscle Anatomy 0.000 claims description 10
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 9
- 238000004020 luminiscence type Methods 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 230000004952 protein activity Effects 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 8
- 239000003184 complementary RNA Substances 0.000 claims description 8
- 230000002222 downregulating effect Effects 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 230000001603 reducing effect Effects 0.000 claims description 8
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 238000002708 random mutagenesis Methods 0.000 claims description 7
- 210000005070 sphincter Anatomy 0.000 claims description 7
- 238000002703 mutagenesis Methods 0.000 claims description 6
- 231100000350 mutagenesis Toxicity 0.000 claims description 6
- 244000163427 Saccharum procerum Species 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 241000283394 Cheumatopsyche ela Species 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 230000017448 oviposition Effects 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 230000004777 loss-of-function mutation Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 101000936917 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 Proteins 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 102000054262 human ATP2A3 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000007355 Sarcoplasmic Reticulum Calcium-Transporting ATPases Human genes 0.000 claims 1
- 108010032750 Sarcoplasmic Reticulum Calcium-Transporting ATPases Proteins 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 abstract description 4
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 description 63
- 238000003556 assay Methods 0.000 description 53
- 241000238631 Hexapoda Species 0.000 description 38
- 239000013598 vector Substances 0.000 description 37
- 239000013612 plasmid Substances 0.000 description 27
- 230000007547 defect Effects 0.000 description 24
- 239000000126 substance Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 108010029485 Protein Isoforms Proteins 0.000 description 21
- 102000001708 Protein Isoforms Human genes 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 238000010367 cloning Methods 0.000 description 21
- 108091030071 RNAI Proteins 0.000 description 20
- 230000009368 gene silencing by RNA Effects 0.000 description 20
- 230000002068 genetic effect Effects 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 101710109123 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 17
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 17
- 210000003800 pharynx Anatomy 0.000 description 17
- 230000003827 upregulation Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 241000018427 Iphisa elegans Species 0.000 description 14
- 101710109122 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Proteins 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 102100027697 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Human genes 0.000 description 13
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 13
- 210000000936 intestine Anatomy 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 230000033001 locomotion Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000005086 pumping Methods 0.000 description 11
- 238000010276 construction Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 101150117157 MYO3 gene Proteins 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 8
- 208000006029 Cardiomegaly Diseases 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 102000009023 sarcolipin Human genes 0.000 description 8
- 108010088766 sarcolipin Proteins 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000002149 gonad Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000575 pesticide Substances 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 101000620634 Sus scrofa Cardiac phospholamban Proteins 0.000 description 6
- 229910052771 Terbium Inorganic materials 0.000 description 6
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000001418 larval effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 229960002378 oftasceine Drugs 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 241000244203 Caenorhabditis elegans Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- CNZIQHGDUXRUJS-UHFFFAOYSA-N Cyclopiazonic acid Natural products CC(=C/1C(=O)C2C3C(Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O)O CNZIQHGDUXRUJS-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- CNZIQHGDUXRUJS-DQYPLSBCSA-N alpha-cyclopiazonic acid Natural products CC(O)=C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O CNZIQHGDUXRUJS-DQYPLSBCSA-N 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- ZKSIPEYIAHUPNM-ZEQRLZLVSA-N butobendine Chemical compound C([C@H](CC)N(C)CCN(C)[C@@H](CC)COC(=O)C=1C=C(OC)C(OC)=C(OC)C=1)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZKSIPEYIAHUPNM-ZEQRLZLVSA-N 0.000 description 4
- 239000013000 chemical inhibitor Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000010448 genetic screening Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000004220 muscle function Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 108010000239 Aequorin Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 208000012766 Growth delay Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000936922 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 3
- 102000006830 Luminescent Proteins Human genes 0.000 description 3
- 108010047357 Luminescent Proteins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 102000054252 human ATP2A2 Human genes 0.000 description 3
- 210000000754 myometrium Anatomy 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002107 sheath cell Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 208000002506 Darier Disease Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 2
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LXWLOFYIORKNSA-FFOGNQQCSA-N [(3s,3ar,4s,6s,6ar,7s,8s,9bs)-6-acetyloxy-4-butanoyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(z)-2-methylbut-2-enoyl]oxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-7-yl] hexanoate Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O LXWLOFYIORKNSA-FFOGNQQCSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 101150031236 ceh-24 gene Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 231100001129 embryonic lethality Toxicity 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 201000004607 keratosis follicularis Diseases 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 101150015886 nuc-1 gene Proteins 0.000 description 2
- 230000034004 oogenesis Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000013363 skeletal muscle disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LXWLOFYIORKNSA-UHFFFAOYSA-N thapsigargicin Natural products CCCC(=O)OC1CC(C)(OC(C)=O)C2C(OC(=O)CCCCC)C(OC(=O)C(C)=CC)C(C)=C2C2OC(=O)C(C)(O)C21O LXWLOFYIORKNSA-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 101150085100 unc-31 gene Proteins 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- GDKBRPGQPSYBTE-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)dodecan-3-one Chemical compound CCCCCCCCCC(=O)CCC1=CC=C(OC)C(OC)=C1 GDKBRPGQPSYBTE-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- 101100257696 Caenorhabditis elegans srf-3 gene Proteins 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102220642993 Cardiac phospholamban_S16A_mutation Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000260546 Carpoglyphus lactis Species 0.000 description 1
- 240000003966 Chrysopogon subtilis Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001131798 Escherichia coli HT115 Species 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101000936731 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 101100247596 Larrea tridentata RCA2 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150068367 PLB gene Proteins 0.000 description 1
- 102220510110 Phospholipid scramblase 3_F258V_mutation Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 240000003085 Quassia amara Species 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- 102000001424 Ryanodine receptors Human genes 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- JVXNCJLLOUQYBF-UHFFFAOYSA-N cyclohex-4-ene-1,3-dione Chemical compound O=C1CC=CC(=O)C1 JVXNCJLLOUQYBF-UHFFFAOYSA-N 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000009427 motor defect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- -1 phenothiazine Chemical class 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102200162479 rs139548132 Human genes 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
- G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12959699P | 1999-04-15 | 1999-04-15 | |
| GB9908670.4 | 1999-04-15 | ||
| GBGB9908670.4A GB9908670D0 (en) | 1999-04-15 | 1999-04-15 | Compound screening method |
| GB9912736.7 | 1999-06-01 | ||
| GB60/129,596 | 1999-06-01 | ||
| GBGB9912736.7A GB9912736D0 (en) | 1999-06-01 | 1999-06-01 | Compound screening methods |
| PCT/IB2000/000558 WO2000063426A2 (en) | 1999-04-15 | 2000-04-14 | Compound screening methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002541859A true JP2002541859A (ja) | 2002-12-10 |
Family
ID=27269699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000612503A Pending JP2002541859A (ja) | 1999-04-15 | 2000-04-14 | 化合物スクリーニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1171628A2 (de) |
| JP (1) | JP2002541859A (de) |
| AU (1) | AU3984700A (de) |
| CA (1) | CA2369478A1 (de) |
| GB (1) | GB2349217B (de) |
| HK (1) | HK1029376A1 (de) |
| WO (1) | WO2000063426A2 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098639A1 (ja) * | 2003-05-08 | 2004-11-18 | Taisho Pharmaceutical Co. Ltd. | ＴＧＦβ由来アポトーシス調節方法 |
| JP2010518885A (ja) * | 2006-09-18 | 2010-06-03 | ユーニヴァーサティ、アヴ、ノース、テクサス | 並列記録能力を有するマルチネットワーク神経細胞分析プラットフォーム |
| JP2016517506A (ja) * | 2013-03-08 | 2016-06-16 | アシスタンス パブリック−ホピトー デ パリ | 線虫類におけるアッセイのための化合物‐担体システム |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2359359B (en) * | 1999-04-15 | 2002-01-23 | Devgen Nv | Compound screening method |
| AU2002218457A1 (en) * | 2000-10-18 | 2002-04-29 | Devgen N.V. | Methods for identifying pesticidal compounds |
| WO2012168474A1 (en) * | 2011-06-10 | 2012-12-13 | Monell Chemical Senses Center | Novel methods |
| CN114794029B (zh) * | 2022-06-09 | 2023-02-28 | 上海大学 | 一种计数秀丽隐杆线虫子宫内发育胚胎数目的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09502163A (ja) * | 1993-06-03 | 1997-03-04 | ザ ユニバーシテイ オブ シドニイ | 天然産物および類縁合成化合物の心臓血管系疾患を治療する用途 |
| FR2753722A1 (fr) * | 1996-09-26 | 1998-03-27 | Smithkline Beecham Lab | Procede de detection de modulateurs de relaxation cardiaque et modulateurs ainsi obtenus |
| WO1998051351A1 (en) * | 1997-05-15 | 1998-11-19 | The General Hospital Corporation | Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| US6329566B1 (en) * | 1997-05-29 | 2001-12-11 | The General Hospital Corporation | Methods for the detection, treatment, and prevention of neurodegeneration |
| EP1009236A4 (de) * | 1997-07-22 | 2000-10-25 | Gen Hospital Corp | Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen |
-
2000
- 2000-04-14 EP EP00919102A patent/EP1171628A2/de not_active Withdrawn
- 2000-04-14 GB GB0009363A patent/GB2349217B/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/IB2000/000558 patent/WO2000063426A2/en not_active Application Discontinuation
- 2000-04-14 JP JP2000612503A patent/JP2002541859A/ja active Pending
- 2000-04-14 CA CA002369478A patent/CA2369478A1/en not_active Abandoned
- 2000-04-14 AU AU39847/00A patent/AU3984700A/en not_active Abandoned
- 2000-12-16 HK HK00108142A patent/HK1029376A1/xx not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098639A1 (ja) * | 2003-05-08 | 2004-11-18 | Taisho Pharmaceutical Co. Ltd. | ＴＧＦβ由来アポトーシス調節方法 |
| JP2010518885A (ja) * | 2006-09-18 | 2010-06-03 | ユーニヴァーサティ、アヴ、ノース、テクサス | 並列記録能力を有するマルチネットワーク神経細胞分析プラットフォーム |
| JP2016517506A (ja) * | 2013-03-08 | 2016-06-16 | アシスタンス パブリック−ホピトー デ パリ | 線虫類におけるアッセイのための化合物‐担体システム |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2369478A1 (en) | 2000-10-26 |
| GB2349217A (en) | 2000-10-25 |
| AU3984700A (en) | 2000-11-02 |
| GB2349217B (en) | 2001-04-04 |
| HK1029376A1 (en) | 2001-03-30 |
| WO2000063426A2 (en) | 2000-10-26 |
| WO2000063426A3 (en) | 2001-02-08 |
| EP1171628A2 (de) | 2002-01-16 |
| GB0009363D0 (en) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tijsterman et al. | Genes required for systemic RNA interference in Caenorhabditis elegans | |
| US6540996B1 (en) | Compound screening methods | |
| EP2622351B1 (de) | Neuropeptid q als gpcr-galr2-modulator und seine verwendung | |
| Lesch et al. | The homeodomain protein hmbx-1 maintains asymmetric gene expression in adult C. elegans olfactory neurons | |
| Mesa et al. | HID-1, a new component of the peptidergic signaling pathway | |
| US6329566B1 (en) | Methods for the detection, treatment, and prevention of neurodegeneration | |
| US5919997A (en) | Transgenic mice having modified cell-cycle regulation | |
| AU780574B2 (en) | Compound screening method | |
| PL208368B1 (pl) | Sposób diagnozowania jaskry | |
| JP2002541859A (ja) | 化合物スクリーニング方法 | |
| JP2004500866A (ja) | Ｃ．ｅｌｅｇａｎｓの成長期依存発現に基づくアッセイ技法 | |
| JP2002511747A (ja) | 耐糖能障害疾患に対する治療および診断ツール | |
| US7125687B1 (en) | Presenilin enhancers assays | |
| Lazakovitch et al. | Lifespan extension and increased pumping rate accompany pharyngeal muscle‐specific expression of nfi‐1 in C. elegans | |
| GB2411403A (en) | Transgenic animals with altered NCS-1 expression | |
| US20120122957A1 (en) | Regulation of aging by modulation of mitochondrial function | |
| US6787125B1 (en) | Compound screening method | |
| US20060115895A1 (en) | Fish disease models and uses thereof | |
| US20100242127A1 (en) | Methods to identify modulators of b-raf protein kinase and their use for the treatment of anxiety and depression | |
| US20060123502A1 (en) | Assay methods for identifying RE2-like antagonists, methods of use, and non-human transgenic animals | |
| GB2359361A (en) | Compound screening method | |
| US20040250299A1 (en) | Compound screening method | |
| CA2683114A1 (en) | Cells expressing alpha-synuclein and uses therefor | |
| Di Monaco | Molecular mechanisms and transcriptional regulation of starvation induced autophagy in drosophila | |
| US20060008800A1 (en) | Unc-13 in the modulation of neurotransmission and secretion events |